Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of ...

This yields a lot of leads, but few pan out. Recursion Pharmaceuticals generates its own data by running 100,000 mini-experiments weekly, robotically dosing samples of “sick” cells with an ...

TAK-733 was identified as a potential treatment for a hereditary tumor syndrome using Recursion’s approach to creating cellular models of diseases where genes are inactive. Using its automated ...

Here's how the $220 billion drug giant is using it. Recursion uses AI tech to both discover and develop drugs for rare diseases, cancer and more. The startup hasn't yet made a drug that you can be ...

SALT LAKE CITY--(BUSINESS WIRE)--Recursion Pharmaceuticals today announced ... revolves around high-throughput automated screening using high-content assays in human cells, which allows the ...